United States: Another Diagnostic Test Found Ineligible Under § 101

Addressing patent eligibility under 35 USC § 101 for gene-related patents, the US Court of Appeals for the Federal Circuit affirmed the district court's grant of summary judgment of invalidity, finding that the primers used to determine the presence of the pathogenic bacteria were indistinguishable from naturally occurring DNA. Roche Molecular Systems, Inc. v. Cepheid, Case No. 17-1690 (Fed. Cir. Oct. 9, 2018) (Reyna, J) (O'Malley, J, concurring).

Roche owns a patent directed to a diagnostic test and methods of using the test to determine the presence of the pathogenic bacteria Mycobacterium tuberculosis (MTB). The underlying technology was based on a discovery by Roche scientists that MTB contains 11 "signature nucleotides" that could be used as a fingerprint identifier. The inventors subsequently developed a diagnostic test involving amplification by polymerase chain reaction (PCR) of a patient's DNA sample to determine if any of the signature nucleotides are present. The resulting patent comprised two types of claims: (1) composition of matter claims for primers used in the PCR, and (2) method of detecting MTB using PCR.

Roche filed a patent infringement case against Cepheid based on its sale of Xpert® MTB/RIF Assay, an assay that can detect MTB in a biological sample and can identify rifampin-resistant MTB. Cepheid filed a motion for summary judgment, arguing that all of the asserted claims were directed to patent-ineligible subject matter under 35 USC § 101. The district court granted Cepheid's motion, finding that the primer claims, which have genetic sequences identical to those found in nature, were indistinguishable from those held to be directed to non-patentable subject matter, and were thus invalid. The court also found that the method claims were invalid because the use of non-patentable primers to bind to newly identified naturally occurring signature nucleotides using the well-known, routine process of PCR in a conventional way does not transform the claimed methods into patent-eligible subject matter. Roche appealed.

The Federal Circuit affirmed. The Court found that the claimed primers were structurally identical to their corresponding nucleotide sequences on the MTB gene found in nature and were thus indistinguishable from those held to be non-patentable subject matter in the Supreme Court of the United States' 2013 decision in Ass'n for Molecular Pathology v. Myriad Genetics, Inc. (IP Update, Vol. 17, No. 6) and the Federal Circuit's 2014 decision in In re BRCA1 (IP Update, Vol. 18, No. 1). In BRCA1 the Court broadly held that DNA primers do not have a different structure from those found in nature and are thus not patent eligible. The Court found nothing that "transformed" the claimed naturally occurring phenomenon into patent-eligible subject matter. Judge O'Malley's concurring opinion agreed that under the holding of BRCA1, the present claims were invalid; however, she proposed that the Court should revisit its holding in BRCA1 at least with respect to the primer claims since the issues raised on appeal were the result of an underdeveloped record.

Turning to the method claims, the Federal Circuit noted that Roche's diagnostic test amounted to a valuable contribution to science, but nonetheless found that the method claims were invalid because they utilized well-known and conventional PCR primers to identify a naturally occurring phenomenon. The Court noted that the method claims assert that if an investigator detects a signature nucleotide from a sample, the investigator knows the sample contains MTB. This relationship exists in nature apart from any human action, meaning that the method claims are directed to a natural phenomenon. While Roche argued that it was unprecedented to use PCR in the detection of MTB, the Court responded that many groundbreaking discoveries had previously been held patent ineligible because they pertained to the discovery of a natural phenomenon. The Court equated Roche's method claims to those diagnostic techniques held invalid in other cases, observing that claims must recite more than simply state a law of nature, simply adding words tantamount to "apply it". The Court distinguished its 2018 decision in Vanda Pharma. v. West-Ward Pharma., Int'l Ltd. (IP Update, Vol. 21, No. 5), where method of treatment claims were found to be subject matter eligible. In Vanda, the inventors recognized the relationships between iloperidone, CYP2D6 metabolism and QTc prolongation, but that is not what they claimed. Instead, they claimed an application of that relationship requiring a treating doctor to administer iloperidone. The Court noted that these cases underscore the distinction between "method of treatment" claims and claims directed to a "diagnostic method." Unlike the Vanda inventors, Roche did not claim a method of treatment based on the detection of MTB, but claimed the natural phenomenon itself.

Practice Note: Given the Federal Circuit's propensity for invalidating diagnostic tests predicated on natural phenomena, it may be advisable to draft such claims as method of treatment claims. For instance, claims directed to a new method of treating tuberculosis, starting with a diagnostic test revealing the presence of the MTB bacteria and ending with a step requiring the doctor to administer the appropriate antibiotic, would likely have been found patentable under the Court's analysis.

Another Diagnostic Test Found Ineligible Under § 101

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions